Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Contineum Therapeutics, Inc. (CTNM)
USD14.16
-0.41 (-2.81%)
US NASDAQ Healthcare Biotechnology
Address
3565 General Atomics Court Suite 200 92121
San Diego, CA, US
San Diego, CA, US
CEO
Carmine N. Stengone
Website
contineum-tx.com
IPO
2024-04-04
CIK 1855175 ISIN US21217B1008
Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
News Sentiment (7d)
Based on only 1 article — low confidence
- Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD14.16
-0.41 (-2.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
302.4K
Beta
0.89
Float Shares
27.59M
Free Float %
73.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.35% | -2.60% | +5.23% | -12.06% | +21.86% | +18.02% | +268.58% | -12.40% | -12.40% | -12.40% | -12.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
14.16
Low
16.00
+13.0%
Consensus
16.00
+13.0%
Median
16.00
+13.0%
High
16.00
+13.0%
DCF (Unlevered)
2.40
-83.1%
DCF (Levered)
2.43
-82.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
16.00
+13.0%
|
| Last Quarter | 1 |
16.00
+13.0%
|
| Last Year | 5 |
17.20
+21.5%
|
| All Time | 9 |
21.44
+51.4%
|
Quality scores
Altman Z-Score
26.04
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-33.1% Q1'26: +37.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-1,073.0% Q1'26: -633.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.1% Q1'26: +44.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.12× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 5 EPS Ana. |
Dec 2027 2 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
50.00M
est: 50.00M (+0.0%)
|
—
|
—
est: 6.00M (-100.0%)
|
6.88M
6.88M – 6.88M
+14.7% YoY
|
2.20M
2.20M – 2.20M
-68.0% YoY
|
3.43M
3.43M – 3.43M
+56.1% YoY
|
22.79M
22.79M – 22.79M
+563.8% YoY
|
25.39M
25.39M – 25.39M
+11.4% YoY
|
| EBITDA |
23.57M
est: 44.71M (-47.3%)
|
-42.00M
|
-67.74M
est: 5.37M (-1,362.4%)
|
6.16M
6.16M – 6.16M
+14.7% YoY
|
1.97M
1.97M – 1.97M
-68.0% YoY
|
3.07M
3.07M – 3.07M
+56.1% YoY
|
20.38M
20.38M – 20.38M
+563.8% YoY
|
22.71M
22.71M – 22.71M
+11.4% YoY
|
| EBIT |
23.38M
est: 44.68M (-47.7%)
|
-42.26M
|
-68.06M
est: 5.36M (-1,369.5%)
|
6.15M
6.15M – 6.15M
+14.7% YoY
|
1.97M
1.97M – 1.97M
-68.0% YoY
|
3.07M
3.07M – 3.07M
+56.1% YoY
|
20.36M
20.36M – 20.36M
+563.8% YoY
|
22.69M
22.69M – 22.69M
+11.4% YoY
|
| Net Income |
22.72M
|
-42.26M
est: -37.08M (-14.0%)
|
-59.98M
est: -56.87M (-5.5%)
|
-45.63M
-53.78M – -38.74M
+19.8% YoY
|
-50.26M
-55.40M – -39.12M
-10.1% YoY
|
-52.86M
-52.86M – -52.86M
-5.2% YoY
|
-55.57M
-55.57M – -55.57M
-5.1% YoY
|
-66.97M
-66.97M – -66.97M
-20.5% YoY
|
| SGA |
6.32M
est: 41.26M (-84.7%)
|
12.47M
|
16.54M
est: 4.95M (+234.0%)
|
5.68M
5.68M – 5.68M
+14.7% YoY
|
1.82M
1.82M – 1.82M
-68.0% YoY
|
2.83M
2.83M – 2.83M
+56.1% YoY
|
18.81M
18.81M – 18.81M
+563.8% YoY
|
20.96M
20.96M – 20.96M
+11.4% YoY
|
| EPS |
0.13
|
-1.63
est: -1.92 (+14.9%)
|
-2.17
est: -2.05 (-5.7%)
|
-1.65
-1.94 – -1.40
+19.8% YoY
|
-1.81
-2.00 – -1.41
-10.1% YoY
|
-1.91
-1.91 – -1.91
-5.2% YoY
|
-2.01
-2.01 – -2.01
-5.1% YoY
|
-2.42
-2.42 – -2.42
-20.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-14 | Morgan Stanley | Equal Weight | Equal Weight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-57.17M
OE per share TTM
-1.90
Owner's Yield
-11.35%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
38.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
91
Total invested
398.93M
Insider transactions (90d)
1
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 1.98M | 10.70% | — | 1.98M | — | — | CO | New Jersey | 2024-04-10 | ↗ |
| 2 | Johnson & Johnson Innovation-JJDC, Inc. | 1.98M | 10.70% | — | 1.98M | — | — | CO | New Jersey | 2024-04-10 | ↗ |
| 3 | Aaron Cowen | 1.72M | 9.30% | — | 1.72M | — | 1.72M | HC, IN | Delaware | 2024-04-15 | ↗ |
| 4 | Suvretta Capital Management, LLC | 1.72M | 9.30% | — | 1.72M | — | 1.72M | IA, OO | Delaware | 2024-04-15 | ↗ |
| 5 | Joseph Edelman | 1.57M | 8.50% | — | 1.57M | — | 1.57M | IN | Delaware | 2024-04-15 | ↗ |
| 6 | Perceptive Advisors LLC | 1.57M | 8.50% | — | 1.57M | — | 1.57M | IA | Delaware | 2024-04-15 | ↗ |
| 7 | Perceptive Life Sciences Master Fund, Ltd. | 1.57M | 8.50% | — | 1.57M | — | 1.57M | CO | Delaware | 2024-04-15 | ↗ |
| 8 | Averill Master Fund, Ltd. | 1.53M | 8.30% | — | 1.53M | — | 1.53M | CO | Delaware | 2024-04-15 | ↗ |
| 9 | s. | 950.9K | 5.00% | 950.9K | — | 950.9K | — | HC | Switzerland | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
91
+9 vs prev Q
New positions
22
Closed positions
12
Increased
51
Reduced
21
Put/Call ratio
0.00
Calls held
11.3K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 2.84M +1.1M (+65.2%) | 32.48M +12.3M (+60.7%) | 10.11% +3.464 pp | 0.67% +0.148 pp | USD17.22 -33.6% | 7 qtrs — |
| 2 | JANUS HENDERSON GROUP PLC | 2.45M +2.4M (+100.0%) | 27.91M +27.9M (+100.0%) | 8.71% +8.710 pp | 0.01% +0.013 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 2.18M +57.7K (+2.7%) | 24.91M -19.4K (-0.1%) | 7.75% -0.442 pp | 0.26% -0.052 pp | USD11.74 -2.6% | 2 qtrs — |
| 4 | JOHNSON & JOHNSON | 1.98M +— (+0.0%) | 22.62M -633.3K (-2.7%) | 7.04% -0.603 pp | 4.08% -0.515 pp | USD21.00 -45.6% | 7 qtrs — |
| 5 | FRANKLIN RESOURCES INC | 1.88M +223.8K (+13.5%) | 21.48M +2.0M (+10.4%) | 6.68% +0.291 pp | 0.01% +0.000 pp | USD17.04 -32.9% | 7 qtrs — |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 1.84M +891.5K (+93.7%) | 21.06M +9.9M (+88.4%) | 6.55% +2.881 pp | 0.03% +0.013 pp | USD11.60 -1.5% | 2 qtrs — |
| 7 | PERCEPTIVE ADVISORS LLC | 1.46M +750.0K (+105.0%) | 16.74M +8.3M (+99.4%) | 5.21% +2.450 pp | 0.30% +0.056 pp | USD16.00 -28.6% | 7 qtrs — |
| 8 | BAKER BROS. ADVISORS LP | 1.42M +1.3M (+1,729.3%) | 16.24M +15.3M (+1,679.5%) | 5.05% +4.754 pp | 0.10% +0.089 pp | USD11.95 -4.4% | 7 qtrs — |
| 9 | VANGUARD GROUP INC | 1.27M +306.6K (+31.8%) | 14.53M +3.2M (+28.2%) | 4.52% +0.797 pp | 0.00% +0.000 pp | USD15.49 -26.2% | 7 qtrs — |
| 10 | MILLENNIUM MANAGEMENT LLC | 830.7K +184.7K (+28.6%) | 9.49M +1.9M (+25.1%) | 2.95% +0.460 pp | 0.00% +0.001 pp | USD10.44 +9.5% | 3 qtrs — |
| 11 | COMMODORE CAPITAL LP | 816.3K +816.3K (+100.0%) | 9.33M +9.3M (+100.0%) | 2.90% +2.904 pp | 0.62% +0.621 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 12 | FMR LLC | 814.9K +— (+0.0%) | 9.31M -260.8K (-2.7%) | 2.90% -0.248 pp | 0.00% +0.000 pp | USD17.55 -34.9% | 7 qtrs — |
| 13 | SECTORAL ASSET MANAGEMENT INC | 800.8K +— (+0.0%) | 9.15M -256.3K (-2.7%) | 2.85% -0.244 pp | 7.34% +1.529 pp | USD21.00 -45.6% | 7 qtrs — |
| 14 | GREAT POINT PARTNERS LLC | 800.0K +800.0K (+100.0%) | 9.14M +9.1M (+100.0%) | 2.85% +2.845 pp | 2.96% +2.965 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 15 | POINT72 ASSET MANAGEMENT, L.P. | 759.2K +391.6K (+106.5%) | 8.68M +4.4M (+100.9%) | 2.70% +1.281 pp | 0.01% +0.003 pp | USD7.82 +46.2% | 3 qtrs — |
| 16 | HHLR ADVISORS, LTD. | 669.3K +— (+0.0%) | 7.65M -214.2K (-2.7%) | 2.38% -0.204 pp | 0.25% +0.054 pp | USD21.00 -45.6% | 7 qtrs — |
| 17 | RED TREE MANAGEMENT, LLC | 638.2K +— (+0.0%) | 7.29M -204.2K (-2.7%) | 2.27% -0.195 pp | 6.69% -2.354 pp | USD14.65 -22.0% | 5 qtrs — |
| 18 | VERSANT VENTURE MANAGEMENT, LLC | 542.6K +— (+0.0%) | 6.20M -173.6K (-2.7%) | 1.93% -0.165 pp | 4.11% +1.105 pp | USD21.00 -45.6% | 7 qtrs — |
| 19 | BLACKROCK, INC. | 536.2K +214.1K (+66.5%) | 6.13M +2.3M (+62.0%) | 1.91% +0.663 pp | 0.00% +0.000 pp | USD13.38 -14.6% | 6 qtrs — |
| 20 | BOXER CAPITAL MANAGEMENT, LLC | 494.0K +494.0K (+100.0%) | 5.65M +5.6M (+100.0%) | 1.76% +1.757 pp | 1.24% +1.236 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 21 | LONGAEVA PARTNERS L.P. | 470.0K +470.0K (+100.0%) | 5.37M +5.4M (+100.0%) | 1.67% +1.672 pp | 0.45% +0.451 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 22 | SILVERARC CAPITAL MANAGEMENT, LLC | 307.5K +141.4K (+85.1%) | 3.52M +1.6M (+80.0%) | 1.09% +0.452 pp | 0.49% +0.225 pp | USD11.60 -1.5% | 2 qtrs — |
| 23 | IKARIAN CAPITAL, LLC | 282.9K +282.9K (+100.0%) | 3.23M +3.2M (+100.0%) | 1.01% +1.006 pp | 0.25% +0.252 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 24 | ADAR1 CAPITAL MANAGEMENT, LLC | 279.0K +201.0K (+257.8%) | 3.19M +2.3M (+248.1%) | 0.99% +0.691 pp | 0.23% +0.148 pp | USD11.30 +1.2% | 6 qtrs — |
| 25 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 265.8K +61.6K (+30.2%) | 3.04M +639.3K (+26.7%) | 0.95% +0.157 pp | 0.00% +0.000 pp | USD11.24 +1.7% | 4 qtrs — |
| 26 | GEODE CAPITAL MANAGEMENT, LLC | 213.9K +2.8K (+1.3%) | 2.45M -35.4K (-1.4%) | 0.76% -0.054 pp | 0.00% +0.000 pp | USD14.06 -18.7% | 7 qtrs — |
| 27 | AMERIPRISE FINANCIAL INC | 209.6K +209.6K (+100.0%) | 2.40M +2.4M (+100.0%) | 0.75% +0.746 pp | 0.00% +0.001 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 28 | UBS GROUP AG | 199.4K +130.9K (+191.1%) | 2.28M +1.5M (+183.1%) | 0.71% +0.445 pp | 0.00% +0.000 pp | USD11.68 -2.1% | 7 qtrs — |
| 29 | MARSHALL WACE, LLP | 180.8K -12.7K (-6.6%) | 2.07M -206.9K (-9.1%) | 0.64% -0.104 pp | 0.00% 0.000 pp | USD11.44 -0.1% | 5 qtrs — |
| 30 | SPHERA FUNDS MANAGEMENT LTD. | 173.5K +173.5K (+100.0%) | 1.98M +2.0M (+100.0%) | 0.62% +0.617 pp | 0.38% +0.383 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 31 | CASDIN CAPITAL, LLC | 148.3K +— (+0.0%) | 1.70M -47.5K (-2.7%) | 0.53% -0.045 pp | 0.11% -0.040 pp | USD21.00 -45.6% | 7 qtrs — |
| 32 | EVERSEPT PARTNERS, LP | 137.5K +2.9K (+2.1%) | 1.57M -10.2K (-0.6%) | 0.49% -0.031 pp | 0.08% -0.030 pp | USD11.74 -2.6% | 2 qtrs — |
| 33 | MONASHEE INVESTMENT MANAGEMENT LLC | 137.4K +137.4K (+100.0%) | 1.57M +1.6M (+100.0%) | 0.49% +0.489 pp | 0.89% +0.885 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 34 | MORGAN STANLEY | 124.3K +31.3K (+33.6%) | 1.42M +327.9K (+30.0%) | 0.44% +0.083 pp | 0.00% +0.000 pp | USD9.79 +16.8% | 7 qtrs — |
| 35 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 110.1K -117.0 (-0.1%) | 1.26M -36.6K (-2.8%) | 0.39% -0.034 pp | 0.00% +0.000 pp | USD13.61 -16.0% | 7 qtrs — |
| 36 | GOLDMAN SACHS GROUP INC | 105.6K +75.5K (+250.4%) | 1.21M +852.9K (+240.9%) | 0.38% +0.259 pp | 0.00% +0.000 pp | USD10.01 +14.2% | 5 qtrs — |
| 37 | 683 CAPITAL MANAGEMENT, LLC | 91.4K +91.4K (+100.0%) | 1.05M +1.0M (+100.0%) | 0.33% +0.325 pp | 0.05% +0.046 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 38 | STATE STREET CORP | 84.4K +22.0K (+35.2%) | 965.0K +231.5K (+31.6%) | 0.30% +0.059 pp | 0.00% +0.000 pp | USD14.45 -20.9% | 7 qtrs — |
| 39 | BOOTHBAY FUND MANAGEMENT, LLC | 72.5K +72.5K (+100.0%) | 828.6K +828.6K (+100.0%) | 0.26% +0.258 pp | 0.01% +0.012 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 40 | SAMSARA BIOCAPITAL, LLC | 72.2K -498.9K (-87.4%) | 825.8K -5.9M (-87.7%) | 0.26% -1.949 pp | 0.09% -0.791 pp | USD21.00 -45.6% | 7 qtrs — |
| 41 | ACADIAN ASSET MANAGEMENT LLC | 64.7K +38.2K (+144.4%) | 735.0K +427.0K (+138.6%) | 0.23% +0.128 pp | 0.00% +0.001 pp | USD10.91 +4.8% | 3 qtrs — |
| 42 | BNP PARIBAS ARBITRAGE, SNC | 64.2K +64.0K (+29,094.5%) | 734.1K +731.5K (+28,299.5%) | 0.23% +0.228 pp | 0.00% +0.000 pp | USD11.46 -0.3% | 7 qtrs — |
| 43 | BARCLAYS PLC | 59.5K +51.2K (+616.3%) | 680.2K +521.2K (+327.7%) | 0.21% +0.180 pp | 0.00% +0.000 pp | USD11.63 -1.7% | 7 qtrs — |
| 44 | TREXQUANT INVESTMENT LP | 59.0K +29.7K (+101.4%) | 674.7K +330.3K (+95.9%) | 0.21% +0.097 pp | 0.01% +0.003 pp | USD11.59 -1.4% | 2 qtrs — |
| 45 | RENAISSANCE TECHNOLOGIES LLC | 57.1K +15.9K (+38.6%) | 652.7K +168.6K (+34.8%) | 0.20% +0.044 pp | 0.00% +0.000 pp | USD9.70 +17.8% | 3 qtrs — |
| 46 | NORTHERN TRUST CORP | 53.9K +4.9K (+10.0%) | 615.8K +40.5K (+7.0%) | 0.19% +0.003 pp | 0.00% +0.000 pp | USD14.74 -22.5% | 7 qtrs — |
| 47 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 51.0K +51.0K (+100.0%) | 583.3K +583.3K (+100.0%) | 0.18% +0.182 pp | 0.00% +0.005 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 48 | STRATEGIES WEALTH ADVISORS, LLC | 50.0K +— (+0.0%) | 571.5K -16.0K (-2.7%) | 0.18% -0.015 pp | 0.06% -0.004 pp | USD9.31 +22.8% | 5 qtrs — |
| 49 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 49.3K +7.7K (+18.5%) | 563.3K +74.7K (+15.3%) | 0.18% +0.015 pp | 0.01% +0.001 pp | USD8.67 +31.8% | 3 qtrs — |
| 50 | QUBE RESEARCH & TECHNOLOGIES LTD | 43.1K +43.1K (+100.0%) | 492.4K +492.4K (+100.0%) | 0.15% +0.153 pp | 0.00% +0.001 pp | USD11.43 +0.0% | 3 qtrs — |
| 51 | TWO SIGMA INVESTMENTS, LP | 37.9K -27.0 (-0.1%) | 433.4K -12.5K (-2.8%) | 0.13% -0.012 pp | 0.00% 0.000 pp | USD3.97 +187.9% | 3 qtrs — |
| 52 | OMERS ADMINISTRATION CORP | 34.9K +34.9K (+100.0%) | 398.9K +398.9K (+100.0%) | 0.12% +0.124 pp | 0.00% +0.003 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 53 | JANE STREET GROUP, LLC | 27.9K +27.9K (+100.0%) | 319.4K +319.4K (+100.0%) | 0.10% +0.099 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 3 qtrs — |
| 54 | HUDSON BAY CAPITAL MANAGEMENT LP | 25.9K +25.9K (+100.0%) | 296.5K +296.5K (+100.0%) | 0.09% +0.092 pp | 0.00% +0.001 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 55 | QUADRATURE CAPITAL LTD | 23.4K +23.4K (+100.0%) | 267.2K +267.2K (+100.0%) | 0.08% +0.083 pp | 0.00% +0.003 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 56 | SCHONFELD STRATEGIC ADVISORS LLC | 22.7K +4.2K (+22.6%) | 259.2K +41.8K (+19.2%) | 0.08% +0.009 pp | 0.00% 0.000 pp | USD12.28 -6.9% | 5 qtrs — |
| 57 | RBF CAPITAL, LLC | 20.0K -20.0K (-50.0%) | 228.6K -241.4K (-51.4%) | 0.07% -0.083 pp | 0.01% -0.011 pp | USD3.97 +187.9% | 3 qtrs — |
| 58 | AMERICAN CENTURY COMPANIES INC | 19.5K +19.5K (+100.0%) | 223.1K +223.1K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 59 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 19.4K +19.4K (+100.0%) | 222.0K +222.0K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.002 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 60 | GRAHAM CAPITAL MANAGEMENT, L.P. | 17.1K +17.1K (+100.0%) | 195.2K +195.2K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.005 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 61 | OCCUDO QUANTITATIVE STRATEGIES LP | 15.0K +15.0K (+100.0%) | 171.9K +171.9K (+100.0%) | 0.05% +0.054 pp | 0.01% +0.012 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 62 | PERSISTENT ASSET PARTNERS LTD | 13.9K +13.9K (+100.0%) | 158.3K +158.3K (+100.0%) | 0.05% +0.049 pp | 0.07% +0.071 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 63 | CITIGROUP INC | 12.3K +12.3K (+100.0%) | 140.9K +140.9K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 7 qtrs — |
| 64 | PRICE T ROWE ASSOCIATES INC /MD/ | 11.3K +11.3K (+100.0%) | 130.0K +130.0K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 65 | BANK OF AMERICA CORP /DE/ | 9.3K +2.0K (+28.1%) | 105.9K +20.9K (+24.6%) | 0.03% +0.005 pp | 0.00% +0.000 pp | USD12.53 -8.8% | 7 qtrs — |
| 66 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 3.8K +3.8K (+100.0%) | 43.0K +43.0K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.003 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 67 | ROYAL BANK OF CANADA | 3.3K +511.0 (+18.1%) | 38.0K +5.0K (+15.2%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD5.87 +94.7% | 7 qtrs — |
| 68 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 2.6K +— (+0.0%) | 29.3K -819.0 (-2.7%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD3.97 +187.9% | 3 qtrs — |
| 69 | JPMORGAN CHASE & CO | 1.8K +1.8K (+100.0%) | 20.5K +20.5K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 7 qtrs — |
| 70 | CWM, LLC | 1.2K -69.0 (-5.5%) | 13.0K -2.0K (-13.3%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD4.42 +158.6% | 6 qtrs — |
| 71 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 1.1K +1.1K (+100.0%) | 12.8K +12.8K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 72 | GF FUND MANAGEMENT CO. LTD. | 454.00 +454.0 (+100.0%) | 5.2K +5.2K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 73 | FORTITUDE FAMILY OFFICE, LLC | 445.00 +— (+0.0%) | 5.1K -143.0 (-2.7%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD11.75 -2.7% | 2 qtrs — |
| 74 | BANQUE TRANSATLANTIQUE SA | 220.00 +220.0 (+100.0%) | 2.5K +2.5K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.43 +0.0% | 1 qtrs NEW |
| 75 | TOWER RESEARCH CAPITAL LLC (TRC) | 124.00 -1.6K (-92.6%) | 1.4K -18.3K (-92.8%) | 0.00% -0.006 pp | 0.00% -0.001 pp | USD5.80 +97.1% | 7 qtrs — |
| 76 | OPTIVER HOLDING B.V. | 104.00 +— (+0.0%) | 1.2K -33.0 (-2.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.75 -2.7% | 2 qtrs — |
| 77 | GROUP ONE TRADING, L.P. | 103.00 -397.0 (-79.4%) | 1.2K -4.7K (-80.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD11.75 -2.7% | 2 qtrs — |
| 78 | — | 64.00 +64.0 (+100.0%) | 732.00 +732.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD11.42 +0.1% | 1 qtrs NEW |
| 79 | SQUAREPOINT OPS LLC | — -13.1K (-100.0%) | — -153.8K (-100.0%) | 0.00% -0.051 pp | 0.00% 0.000 pp | USD— | 7 qtrs SOLD |
| 80 | IFP ADVISORS, INC | — -1.0 (-100.0%) | — -12.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 81 | SIMPLEX TRADING, LLC | — -895.0 (-100.0%) | — -10.0K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 82 | EVERSOURCE WEALTH ADVISORS, LLC | — -48.0 (-100.0%) | — -564.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 83 | TRUE WEALTH DESIGN, LLC | — -38.0 (-100.0%) | — -447.0 (-100.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 84 | MARINER, LLC | — -10.4K (-100.0%) | — -122.4K (-100.0%) | 0.00% -0.040 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 85 | SBI SECURITIES CO., LTD. | — -1.0 (-100.0%) | — -12.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 86 | BAKER ELLIS ASSET MANAGEMENT LLC | — -19.5K (-100.0%) | — -229.1K (-100.0%) | 0.00% -0.075 pp | 0.00% -0.028 pp | USD— | 2 qtrs SOLD |
| 87 | BAILARD, INC. | — -12.4K (-100.0%) | — -145.1K (-100.0%) | 0.00% -0.048 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
| 88 | WELLS FARGO & COMPANY/MN | — -5.4K (-100.0%) | — -63.0K (-100.0%) | 0.00% -0.021 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 89 | SRS CAPITAL ADVISORS, INC. | — -8.0 (-100.0%) | — -94.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 51 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.25% | 542.7K | 0.50% |
| 2 | iShares Micro-Cap ETF IWC | 0.09% | 1.37M | 0.60% |
| 3 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.05% | 515.4K | 0.20% |
| 4 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 158.1K | 0.40% |
| 5 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 25.5K | 0.19% |
| 6 | iShares Biotechnology ETF IBB | 0.03% | 3.18M | 0.44% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 23.9K | 0.35% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 357.2K | 0.35% |
| 9 | iShares Russell 2000 Value ETF IWN | 0.03% | 3.67M | 0.24% |
| 10 | Avantis U.S. Small Cap Equity ETF AVSC | 0.02% | 700.8K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
8.3K
Cash buys
—
Cash sales
3.00
Net activity
-8,340
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 3,870 | 13.06 | 50.5K | 143,842 | D | ↗ |
| 2026-04-06 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 4,170 | 13.43 | 56.0K | 147,712 | D | ↗ |
| 2026-03-02 | Watkins Tim | Officer | M-Exempt | D | Stock Option (right to buy) | 3,611 | 4.50 | 16.2K | 249,167 | D | ↗ |
| 2026-03-02 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 4,170 | 15.01 | 62.6K | 151,882 | D | ↗ |
| 2026-02-25 | Stengone Carmine N. | Director / Officer | M-Exempt | A | Class A Common Stock | 2,700 | 1.26 | 3.4K | 17,654 | D | ↗ |
| 2026-02-25 | Lorrain Daniel S. | Officer | M-Exempt | D | Stock Option (right to buy) | 3,824 | 1.01 | 3.9K | 67,306 | D | ↗ |
| 2026-02-24 | Stengone Carmine N. | Director / Officer | S-Sale | D | Class A Common Stock | 4,400 | 16.02 | 70.5K | 14,954 | D | ↗ |
| 2026-02-24 | Lorrain Daniel S. | Officer | M-Exempt | A | Class A Common Stock | 4,300 | 1.01 | 4.3K | 160,352 | D | ↗ |
| 2026-02-19 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 100 | 16.00 | 1.6K | 156,052 | D | ↗ |
| 2026-02-11 | Stengone Carmine N. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 400 | 1.26 | 504.00 | 128,017 | D | ↗ |
| 2026-02-11 | Lorrain Daniel S. | Officer | M-Exempt | A | Class A Common Stock | 400 | 1.01 | 404.00 | 156,452 | D | ↗ |
| 2026-02-03 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 3,000 | 14.82 | 44.5K | 157,222 | D | ↗ |
| 2026-01-30 | Watkins Tim | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 14.26 | 2.28M | 160,000 | D | ↗ |
| 2026-01-30 | Stengone Carmine N. | Director / Officer | A-Award | A | Stock Option (right to buy) | 445,000 | 14.26 | 6.35M | 445,000 | D | ↗ |
| 2026-01-30 | Slover Peter T | Officer | A-Award | A | Stock Option (right to buy) | 192,000 | 14.26 | 2.74M | 192,000 | D | ↗ |
| 2026-01-30 | Lorrain Daniel S. | Officer | A-Award | A | Stock Option (right to buy) | 160,000 | 14.26 | 2.28M | 160,000 | D | ↗ |
| 2026-01-30 | Healy John Stephen | Officer | A-Award | A | Stock Option (right to buy) | 206,411 | 14.26 | 2.94M | 206,411 | D | ↗ |
| 2026-01-28 | Watkins Tim | Officer | M-Exempt | D | Stock Option (right to buy) | 3,611 | 4.50 | 16.2K | 252,778 | D | ↗ |
| 2026-01-05 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 3,670 | 10.35 | 38.0K | 160,722 | D | ↗ |
| 2025-12-29 | Watkins Tim | Officer | M-Exempt | D | Stock Option (right to buy) | 3,611 | 4.50 | 16.2K | 256,389 | D | ↗ |
| 2025-12-23 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 4,170 | 12.23 | 51.0K | 164,392 | D | ↗ |
| 2025-06-26 | Ware Olivia C | Director | A-Award | A | Stock Option (right to buy) | 14,750 | 4.01 | 59.1K | 14,750 | D | ↗ |
| 2025-06-26 | Schimmelpennink Evert B. | Director | A-Award | A | Stock Option (right to buy) | 14,750 | 4.01 | 59.1K | 14,750 | D | ↗ |
| 2025-06-26 | Miralles Gines Diego | Director | A-Award | A | Stock Option (right to buy) | 14,750 | 4.01 | 59.1K | 14,750 | D | ↗ |
| 2025-06-26 | Lyons-Williams Lori | Director | A-Award | A | Stock Option (right to buy) | 14,750 | 4.01 | 59.1K | 14,750 | D | ↗ |
| 2025-06-26 | Ignelzi Troy A. | Director | A-Award | A | Stock Option (right to buy) | 14,750 | 4.01 | 59.1K | 14,750 | D | ↗ |
| 2025-06-26 | Brady Todd R. | Director | A-Award | A | Stock Option (right to buy) | 14,750 | 4.01 | 59.1K | 14,750 | D | ↗ |
| 2025-06-26 | Boyce Sarah | Director | A-Award | A | Stock Option (right to buy) | 14,750 | 4.01 | 59.1K | 14,750 | D | ↗ |
| 2025-04-28 | Watkins Tim | Officer | A-Award | A | Stock Option (right to buy) | 260,000 | 4.50 | 1.17M | 260,000 | D | ↗ |
| 2025-03-14 | Miralles Gines Diego | Director | A-Award | A | Stock Option (right to buy) | 29,500 | 6.67 | 196.8K | 29,500 | D | ↗ |
| 2025-01-31 | Stengone Carmine N. | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 9.79 | 2.94M | 300,000 | D | ↗ |
| 2025-01-31 | Slover Peter T | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 9.79 | 1.08M | 110,000 | D | ↗ |
| 2025-01-31 | Lorrain Daniel S. | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 9.79 | 1.08M | 110,000 | D | ↗ |
| 2025-01-31 | Huhn Stephen L. | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 9.79 | 1.08M | 110,000 | D | ↗ |
| 2025-01-31 | Healy John Stephen | Officer | A-Award | A | Stock Option (right to buy) | 63,589 | 9.79 | 622.5K | 63,589 | D | ↗ |
| 2024-11-25 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 1,010 | 16.02 | 16.2K | 168,562 | D | ↗ |
| 2024-11-18 | Lorrain Daniel S. | Officer | S-Sale | D | Class A Common Stock | 6,091 | 16.37 | 99.7K | 169,671 | D | ↗ |
| 2024-04-09 | JOHNSON & JOHNSON | 10% Owner | — | I | Class A Common Stock | 0 | 0.00 | — | 1,979,173 | — | ↗ |
Executive team
Top executives
Shares Outstanding
37.39M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Carmine N. Stengone President and Chief Executive Officer | 655.6K | — | — | 2.29M | 450.7K | 11.4K | 3.41M | 67.21% | ↗ |
| 2 | 2025 | Timothy R. Watkins, M.D., MSc. Chief Medical Officer and Head of Development | 359.5K | 225.0K | — | 984.6K | 176.1K | 18.2K | 1.76M | 55.84% | ↗ |
| 3 | 2025 | Peter T. Slover Chief Financial Officer | 487.5K | — | — | 840.3K | 238.9K | 11.3K | 1.58M | 53.25% | ↗ |
| 4 | 2024 | Carmine N. Stengone President and Chief Executive Officer | 608.1K | 55.0K | — | 3.81M | 418.1K | 12.6K | 4.90M | 77.68% | ↗ |
| 5 | 2024 | John S. Healy General Counsel and Corporate Secretary | 254.7K | — | — | 2.13M | 123.7K | 52.6K | 2.56M | 83.18% | ↗ |
| 6 | 2024 | Stephen L. Huhn Former Chief Medical Officer and Senior Vice President of Clinical Development | 485.4K | 55.0K | — | 1.34M | 233.0K | 12.8K | 2.12M | 62.95% | ↗ |
| 7 | 2023 | Carmine N. Stengone President and Chief Executive Officer | 515.6K | 55.0K | — | 1.53M | 207.5K | 12.2K | 2.32M | 65.87% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carmine N. Stengone | President, Chief Executive Officer & Director | 1M | male |
| Timothy R. Watkins | Chief Medical Officer & Head of Development | 778.8K | — |
| Peter T. Slover | Chief Financial Officer | 737.6K | male |
| John Healy | General Counsel & Corporate Secretary | 612.8K | male |
| Daniel S. Lorrain | Chief Science Officer | 565.0K | — |
| Steve E. Kunszabo | Senior Director of Investor Relations & Corporate Communications | — | male |
| Julie S. Iwashita | Senior Vice President of Clinical Operations | — | female |
| Jennifer Patterson | Vice President of Human Resources | — | female |
| Austin Chen | Senior Vice President & Head of Research | — | male |
| Kristina Haeckl Rac | Senior Vice President of Regulatory Affairs | — | female |
| Morgan Paulsen | Senior Manager of Accounting | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTNM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
